Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

NCT00447642 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

122

Enrollment

INDUSTRY

Sponsor class

Stopped The primary efficacy endpoint was not met

Conditions

Corneal Transplantation
Corneal Graft Rejection

Interventions

DRUG: LX201
OTHER: Placebo

Sponsor

Lux Biosciences, Inc.